Safinamide in the treatment of Parkinson's disease.

Abstract:

IMPORTANCE OF THE FIELD:Current therapy for Parkinson's disease (PD) is primarily directed at reversing the motor symptoms that are the consequence of dopamine deficiency and includes levodopa, dopamine agonists and monoamine oxidase (MAO) B inhibitors. New drugs offering both dopaminergic and non-dopaminergic actions could offer a significant advantage. AREAS COVERED IN THIS REVIEW:This review surveys the current treatment strategies for PD. Defining unmet needs and how a new compound - safinamide, which has both dopaminergic and non-dopaminergic actions - might address these. WHAT THE READER WILL GAIN:The reader will gain an understanding of safinamide and its mechanisms of action, including reversible MAOB inhibition and reduced dopamine reuptake with antiglutamatergic effects, and how it may potentially provide improvement of PD motor symptoms with an antidyskinetic effect through its effect on glutamate release. The clinical trial profile of safinamide is reviewed. Early results are promising in terms of improved motor function and reduced 'OFF' time. Additional Phase III trials are now in progress for this adjunctive indication. Finally, the reader will understand the potential role for safinamide in the selection and sequencing of drugs for PD. TAKE HOME MESSAGE:safinamide combines both dopaminergic and non-dopaminergic actions that may add a new dimension to PD treatment options as an adjunct to current drugs. Its efficacy is under active evaluation in Phase III clinical trials.

authors

Schapira AH

doi

10.1517/14656566.2010.511612

subject

Has Abstract

pub_date

2010-09-01 00:00:00

pages

2261-8

issue

13

eissn

1465-6566

issn

1744-7666

journal_volume

11

pub_type

杂志文章,评审
  • Economic assessment in the management of non-Hodgkin's lymphoma.

    abstract::An increasing need for economic evaluations of non-Hodgkin's lymphoma (NHL) treatments exists. We performed a literature review on the currently available NHL economic evaluations, using PubMed and the Cochrane database. English and Dutch language papers on treatment in adults were selected. A total of 88 publications...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.12.2529

    authors: van Agthoven M,Uyl-de Groot CA,Sonneveld P,Hagenbeek A

    更新日期:2004-12-01 00:00:00

  • Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.

    abstract:INTRODUCTION:Colorectal cancer (CRC) is the third most common cancer in the western world and also in Japan. The key factors in curing CRC are early detection, surgery and adequate adjuvant chemotherapy if needed. AREAS COVERED:Based on the results of following pivotal adjuvant trials, FOLFOX or XELOX are considered s...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1145665

    authors: Tsuji Y,Sugihara K

    更新日期:2016-01-01 00:00:00

  • Pharmacotherapy options in pulmonary alveolar proteinosis.

    abstract:INTRODUCTION:Pulmonary alveolar proteinosis (PAP) is a heterogeneous group of rare diseases characterized by the abnormal production and impaired degradation of pulmonary surfactant as a result of malfunctioning of alveolar macrophages. This is due to the downstream dysregulation of the GM-CSF pathway, which can be cau...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1757650

    authors: Antoniu SA,Rajnoveanu R,Grigore M,Antohe I

    更新日期:2020-08-01 00:00:00

  • Adjuvant medical therapy for prostate cancer.

    abstract:IMPORTANCE OF THE FIELD:Prostate cancer is a common cancer and the role of adjuvant medical therapy continues to be investigated. An understanding of the use of adjuvant medical therapy is essential for the appropriate care of prostate cancer patients, especially for those with locally advanced or high-risk disease. A...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.516252

    authors: Sumey C,Flaig TW

    更新日期:2011-01-01 00:00:00

  • Is long-term adjuvant treatment of breast cancer with anastrozole indicated?

    abstract:BACKGROUND:Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive breast cancer. OBJECTIVE:To determine whether the aromatase inhibitor anastrozole should replace tamoxifen as the adjuvant treatment in this cancer. METHODS:Two recent trials of anastrozole and tamoxifen as adju...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.9.9.1619

    authors: Doggrell SA

    更新日期:2008-06-01 00:00:00

  • An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.

    abstract:INTRODUCTION:Treatment of unresectable or metastatic urothelial carcinoma (UC) has historically relied upon platinum-based chemotherapy and, more recently, immune checkpoint inhibitors. When tumors progress despite those therapies, remaining effective options are limited. AREAS COVERED:In this review, the authors revi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1736036

    authors: Nauseef JT,Villamar DM,Lebenthal J,Vlachostergios PJ,Tagawa ST

    更新日期:2020-06-01 00:00:00

  • The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin.

    abstract::Gestational diabetes (GD) develops because pregnancy increases requirements for insulin secretion while increasing insulin resistance. Women with GD often have impaired pancreatic beta-cell compensation for insulin resistance. The nature of GD is currently contentious, with debate about its existence, diagnosis and ra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.11.1557

    authors: Glueck CJ,Goldenberg N,Streicher P,Wang P

    更新日期:2002-11-01 00:00:00

  • New treatment options for panic disorder: clinical trials from 2000 to 2010.

    abstract:INTRODUCTION:Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the long...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.562200

    authors: Freire RC,Hallak JE,Crippa JA,Nardi AE

    更新日期:2011-06-01 00:00:00

  • Sorafenib in liver cancer.

    abstract:INTRODUCTION:With growing knowledge of the molecular pathway of carcinogenesis, targeted therapies have become the 'blue ocean' of cancer treatment. sorafenib is an oral multikinase inhibitor that targets Raf/mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) (Raf/MEK/ERK) and several ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.679930

    authors: Woo HY,Heo J

    更新日期:2012-05-01 00:00:00

  • Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.

    abstract:INTRODUCTION:As type 2 diabetes mellitus (T2DM) advances, patients receiving basal insulin will eventually require another agent on top of their current regimen in order to achieve glycemic control. One such agent that can be administered in combination with basal insulin is the glucagon-like peptide-1 receptor agonist...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2016.1206079

    authors: Forst T

    更新日期:2016-08-01 00:00:00

  • Advances in pharmacotherapy of vestibular and ocular motor disorders.

    abstract:INTRODUCTION:Vertigo and dizziness are common chief complaints of vestibular and ocular motor disorders (lifetime prevalence 30%). Treatment relies on physical, pharmacological, psychological and rarely surgical approaches. Eight groups of drugs are currently used in vestibular and ocular motor disorders, namely anti-v...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1610386

    authors: Zwergal A,Strupp M,Brandt T

    更新日期:2019-07-01 00:00:00

  • Treatment modalities for bacterial rhinosinusitis.

    abstract:IMPORTANCE OF THE FIELD:Rhinosinusitis is a common illness that represents a substantial economic burden. The vast majority of cases resolve spontaneously but a small proportion develops a secondary bacterial infection. Accurate diagnosis of rhinosinusitis depends upon clinical assessment. Isolation of the causative ag...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003598901

    authors: Brook I

    更新日期:2010-04-01 00:00:00

  • On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1524874

    authors: Samples LS,Graf SA

    更新日期:2018-10-01 00:00:00

  • Efavirenz: a review.

    abstract::Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.6.851

    authors: Vrouenraets SM,Wit FW,van Tongeren J,Lange JM

    更新日期:2007-04-01 00:00:00

  • Oxybutynin gel for the treatment of overactive bladder.

    abstract:INTRODUCTION:Overactive bladder (OAB) is a common condition that has a profound impact on an individual's overall health and quality of life. Muscarinic receptor antagonists are the mainstay of oral pharmacotherapy for OAB. While all of the medications in this class are significantly more effective than placebo, they a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.688953

    authors: Gomelsky A,Dmochowski RR

    更新日期:2012-06-01 00:00:00

  • Antimicrobial treatment of anaerobic infections.

    abstract:INTRODUCTION:Anaerobes are the most predominant components of normal human skin and mucous membrane bacterial flora and are, therefore, a common cause of endogenous bacterial infections. Because of their fastidious nature, they are difficult to isolate from infectious sites and are often overlooked. Anaerobic infection...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.576672

    authors: Brook I

    更新日期:2011-08-01 00:00:00

  • Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

    abstract:INTRODUCTION:The introduction of novel agents has significantly improved multiple myeloma (MM) patient outcome during the last two decades. MM received the most drug approvals for any one malignancy during this time period, both in the United States as well as in Europe. Areas covered: Proteasome inhibitors, immunomodu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1340942

    authors: Podar K,Pecherstorfer M

    更新日期:2017-08-01 00:00:00

  • The optimal combination therapy for the treatment of early rheumatoid arthritis.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune condition traditionally viewed as a severe destructive disease affecting physical health and global wellbeing. The treatment strategies for RA have changed in the last decades from mainly symptomatic towards a more vigorous and targeted approac...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1056735

    authors: De Cock D,Van der Elst K,Meyfroidt S,Verschueren P,Westhovens R

    更新日期:2015-01-01 00:00:00

  • Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.

    abstract:INTRODUCTION:actinic keratosis is a premalignant disease with a high incidence and is a strong predictor for the development of squamous cell carcinoma. Various treatment options have been established over recent years, including topical treatment with imiquimod, 5-fluorouracil, diclofenac or photodynamic therapy, cryo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.549128

    authors: Quist SR,Gollnick HP

    更新日期:2011-02-01 00:00:00

  • Cost-effectiveness of different postoperative analgesic treatments.

    abstract::Pain may produce metabolic changes after surgery, which may contribute to further morbidity. A variety of medicines and techniques can be used to successfully treat pain. It is postulated that improved analgesia leads to improved outcomes, although analgesics may also contribute to morbidity. This article reviews the ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.9.1507

    authors: Engoren M

    更新日期:2003-09-01 00:00:00

  • Langerhans cell histiocytosis: pragmatic empirism on the road to rational cure.

    abstract::Langerhans cell histiocytosis (LCH) is a rare disease characterized by the accumulation of clonal dendritic cells in different organs. Most recent findings (e.g., activating BRAF mutations) favor the hypothesis that LCH may represent a neoplasm with varying behavior, but the ultimate pathogenesis remains to be uncover...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,社论

    doi:10.1517/14656566.2012.698612

    authors: Minkov M

    更新日期:2012-08-01 00:00:00

  • Dapagliflozin for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Despite the availability of many antihypreglycemic agents, many patients with type 2 diabetes (T2DM) fail to achieve the glycemic treatment goal, primarily due to progressive beta-cell dysfunction, and increased risk of hypoglycemia. AREAS COVERED:The aim of the present article is to review the efficacy a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.812632

    authors: Abdul-Ghani MA,DeFronzo RA

    更新日期:2013-08-01 00:00:00

  • Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract.

    abstract::Somatostatin and its long-acting analogues have been introduced for the treatment of endocrine tumours of the gastrointestinal tract as they have been shown to effectively control symptoms resulting from excessive hormone release in patients with carcinoid, Verner-Morrison and glucagonoma syndromes. This beneficial ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.6.643

    authors: Arnold R,Wied M,Behr TH

    更新日期:2002-06-01 00:00:00

  • Current pharmacotherapy options for gastritis.

    abstract:INTRODUCTION:Gastritis is a broad term, which is used for different conditions by clinicians, endoscopists and pathologists. Classification strategies have led to more congruence between specialists. The histological evaluation of the gastric mucosa is mandatory for diagnosing and classifying gastritis. Main aetiologic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.747510

    authors: den Hollander WJ,Kuipers EJ

    更新日期:2012-12-01 00:00:00

  • Erectile dysfunction, cardiovascular diseases and depression: interaction of therapy.

    abstract::Several studies have revealed the intimate associations between erectile dysfunction (ED), ischemic heart disease (IHD) and depression. Whether the physicians should also screen for the other two components when a patient presents with one component of this triad is still an important question to be answered. These th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903089326

    authors: El-Sakka AI,Shamloul R,Yassin AA

    更新日期:2009-09-01 00:00:00

  • Pharmacotherapy of Paget's disease of bone.

    abstract:INTRODUCTION:Paget's disease of the bone is a common condition in some populations, affecting almost 10% of older adults in western Europe. Though frequently asymptomatic, it can sometimes result in severe disabilities. Timely intervention is now able to arrest disease progression in the majority of patients. AREAS CO...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.662486

    authors: Reid IR

    更新日期:2012-04-01 00:00:00

  • Non-insulin pharmacological therapies for treating type 1 diabetes.

    abstract:INTRODUCTION:Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of int...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1483339

    authors: Frandsen CS,Dejgaard TF,Madsbad S,Holst JJ

    更新日期:2018-06-01 00:00:00

  • Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?

    abstract:INTRODUCTION:For the past three decades, carbapenems played a central role in our antibiotic armamentarium, trusted to effectively treat infections caused by drug-resistant bacteria. The utility of this class of antibiotics has been compromised by the emergence of resistance especially among Enterobacteriaceae. AREAS ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1145658

    authors: Perez F,El Chakhtoura NG,Papp-Wallace KM,Wilson BM,Bonomo RA

    更新日期:2016-01-01 00:00:00

  • Antipsychotic medication: effects on regulation of glucose and lipids.

    abstract::Since the introduction of chlorpromazine in the 1950s, antipsychotics have been used for the treatment of schizophrenia. The phenothiazines were followed by the butyrophenones, particularly haloperidol. With all the movement disorder side effects of these medications (extrapyramidal syndrome, akathisia, tardive dyskin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.10.1571

    authors: Kato MM,Goodnick PJ

    更新日期:2001-10-01 00:00:00

  • Metabolic syndrome management.

    abstract::Overweight, obesity and the metabolic syndrome occur in genetically susceptible individuals with environmental influences, and may be further compounded by other disorders of metabolism or pharmacological therapy that increase insulin resistance or promotes weight gain. Treatment of the metabolic syndrome should focus...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.13.2059

    authors: Stone NJ,Schmeltz LR

    更新日期:2007-09-01 00:00:00